ACIP recommends Pfizer or Moderna vaccine over Johnson & Johnson’s COVID-19 vaccine

Dec. 17, 2021

The Centers for Disease Control & Prevention (CDC) has updated recommendations made by the Advisory Committee on Immunization Practices (ACIP) for the prevention of COVID-19,

ACIP’s unanimous recommendation followed a robust discussion of the latest evidence on vaccine effectiveness, vaccine safety and rare adverse events, and consideration of the U.S. vaccine supply.

Earlier this week the U.S. Food & Drug Administration (FDA) had issued a warning about the use of the Janssen vaccine in patients with Thrombosis (TTS).

The U.S. supply of mRNA vaccines is abundant – with nearly 100 million doses in the field for immediate use. This updated CDC recommendation follows similar recommendations from other countries, including Canada and the United Kingdom.

Given the current state of the pandemic both here and around the world, the ACIP reaffirmed that receiving any vaccine is better than being unvaccinated. Individuals who are unable or unwilling to receive an mRNA vaccine will continue to have access to Johnson & Johnson’s COVID-19 vaccine.

CDC release

More on COVID